Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled study of selexipag (ACT-293987) in pulmonary arterial hypertension
2009-014490-41Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Selexipag with Placebo (2 arms). Primary endpoint: Time to first morbidity or mortality event. Started Nov 2009; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2009-014490-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014490-41.